List of Excipients in Branded Drug VALGANCICLOVIR HYDROCHLORIDE FOR ORAL

Generic Drugs Containing VALGANCICLOVIR HYDROCHLORIDE FOR ORAL

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	valganciclovir hydrochloride	0591-2579	MANNITOL
Actavis Pharma Inc	valganciclovir hydrochloride	0591-2579	SODIUM BENZOATE
Actavis Pharma Inc	valganciclovir hydrochloride	0591-2579	SUCRALOSE
Actavis Pharma Inc	valganciclovir hydrochloride	0591-2579	TARTARIC ACID
AvKARE	valganciclovir hydrochloride	42291-972	MANNITOL
AvKARE	valganciclovir hydrochloride	42291-972	SODIUM BENZOATE
AvKARE	valganciclovir hydrochloride	42291-972	SUCRALOSE

What are the Most Frequently-Used Excipients in VALGANCICLOVIR HYDROCHLORIDE FOR ORAL?

# Of NDCs	Excipient
2	MANNITOL
2	SODIUM BENZOATE
2	SUCRALOSE
2	TARTARIC ACID

Valganciclovir Hydrochloride Oral Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Valganciclovir hydrochloride is an oral prodrug of ganciclovir used primarily for cytomegalovirus treatment and prevention. The market is genericized, and the commercial opportunity is concentrated in formulation quality, oral-solution convenience, pediatric and transplant use, supply reliability, and differentiated excipient systems rather than basic active-ingredient exclusivity.

The principal products are 450 mg film-coated tablets and a powder for oral solution that is reconstituted to 50 mg/mL. Roche’s Valcyte established the reference formulation. Generic competition has removed most conventional product-level pricing power, but valganciclovir remains technically demanding because of its high dose, hydrolytic sensitivity, unpleasant taste, low therapeutic margin, and use in immunocompromised patients.

What dosage forms and excipients are used in oral valganciclovir products?

The two commercially important dosage forms are immediate-release tablets and an extemporaneously reconstituted oral solution.

Dosage form	Strength	Primary commercial use	Key formulation issues
Film-coated tablet	450 mg	Adults and older pediatric patients able to swallow tablets	High drug load, tablet size, dissolution, moisture control
Powder for oral solution	50 mg/mL after reconstitution	Infants, young children, patients unable to swallow tablets	Taste, suspension uniformity, microbial control, dosing accuracy, reconstitution stability

The Valcyte tablet label identifies excipients including povidone, crospovidone, microcrystalline cellulose, stearic acid and colloidal silicon dioxide. The film coating contains standard coating polymers and colorants. The oral-solution powder uses a different excipient platform, including mannitol, povidone, fumaric acid, sodium benzoate, sodium saccharin and flavoring agents. Exact excipient composition should be confirmed against the current FDA labeling record because inactive ingredients can differ between dosage forms and approved manufacturers.[1]

What does each excipient contribute?

Excipient class	Typical function in valganciclovir oral products	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports high-dose tablet manufacture
Povidone	Binder; can improve granule cohesion and wetting	Affects granulation, dissolution and extractables profile
Crospovidone	Superdisintegrant	Important for rapid tablet breakup
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow and blend uniformity
Stearic acid	Lubricant	Excessive levels can slow wetting and dissolution
Mannitol	Bulking agent and mouthfeel modifier	Useful in pediatric powder systems
Fumaric acid	Acidulant and pH-control component	Supports chemical stability and palatability
Sodium benzoate	Preservative	Relevant to multidose oral-solution microbial control
Sodium saccharin	Sweetener	Reduces bitterness but does not fully mask the drug taste
Flavor system	Palatability improvement	A major differentiator in pediatric products
Film-coating polymer	Swallowability, appearance and handling	Can reduce dusting and improve tablet acceptability

Valganciclovir is a high-dose molecule. Excipient selection therefore cannot rely on large quantities of diluent without increasing tablet size or reducing manufacturability. Direct compression may be possible for some powder grades, but wet granulation or dry granulation may provide better content uniformity and flow, depending on particle-size distribution and bulk density.

What excipient strategy best supports generic valganciclovir tablets?

The strongest tablet strategy is usually a conventional, low-risk immediate-release platform with tight control of disintegration and dissolution.

A practical development sequence is:

1. Characterize valganciclovir hydrochloride particle size, polymorphism, moisture uptake and flow.
2. Screen microcrystalline cellulose, mannitol or dibasic calcium phosphate as diluent systems.
3. Use povidone or a comparable binder only at the minimum level needed for granule strength.
4. Use crospovidone or croscarmellose sodium to maintain rapid disintegration.
5. Optimize lubricant concentration and blending time to avoid hydrophobic over-lubrication.
6. Apply a robust film coat that improves handling without materially delaying dissolution.
7. Establish packaging that limits moisture ingress.

A direct-compression formulation can reduce manufacturing steps and cost, but it creates greater dependence on powder flow, segregation control and tablet-weight consistency. Dry granulation can improve flow while avoiding water exposure. Wet granulation may improve uniformity but introduces additional processing and stability considerations.

The main quality attributes are:

• assay and content uniformity;
• dissolution across relevant pH conditions;
• disintegration time;
• related substances and hydrolysis products;
• tablet hardness and friability;
• moisture content;
• stability in the proposed container-closure system.

The commercial objective is not a novel excipient combination by itself. It is a reproducible formulation that matches the reference product’s performance while lowering manufacturing cost and reducing batch failure risk.

What excipient strategy supports valganciclovir oral solution?

The oral solution has greater differentiation potential than the tablet because pediatric administration creates practical problems that conventional bioequivalence testing may not capture fully.

A commercial oral-solution formulation should address four risks:

• strong or persistent bitterness;
• dose-volume errors;
• sedimentation or incomplete redispersion;
• microbial growth after reconstitution.

A powder-for-reconstitution format can improve shelf life before dispensing. The formulation must then provide adequate reconstitution behavior, uniform drug concentration throughout the labeled in-use period and acceptable microbial protection.

Which excipients create the greatest pediatric opportunity?

Taste-masking systems have the highest commercial value. Options include:

• optimized sweetener and flavor combinations;
• polymeric taste-masking agents;
• ion-exchange resins;
• coated drug particles;
• lipid or wax-based microencapsulation;
• pH adjustment to reduce perceived bitterness;
• viscosity modifiers that increase residence-time control in the mouth.

Taste masking cannot impair dose delivery, release or analytical recovery. Ion-exchange and coating approaches can create a more defensible formulation patent position, but they add manufacturing complexity and may complicate dissolution testing.

A second opportunity is a low-error dosing system. An oral syringe calibrated for the 50 mg/mL concentration, a clearly marked bottle fill volume and a reconstitution adapter can reduce dosing mistakes. Device-related improvements may support separate regulatory or design-right strategies, although the drug product remains subject to FDA drug-approval requirements.

What FDA regulatory status applies to oral valganciclovir?

Valganciclovir hydrochloride is an FDA-approved small-molecule drug. Valcyte was approved in 2001. The reference product includes tablet and oral-solution presentations for CMV-related indications, including treatment of CMV retinitis in adults with AIDS and prevention of CMV disease in high-risk transplant settings.[1]

Generic products are approved through abbreviated new drug applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Generic applicants generally must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. A new oral solution or a materially differentiated formulation may require a different regulatory strategy if it cannot rely on the same reference-product pathway.

For a conventional generic, the principal regulatory issues are:

• bioequivalence of the 450 mg tablet;
• comparative dissolution;
• inactive-ingredient suitability;
• stability and impurity control;
• container-closure performance;
• manufacturing controls for high-dose tablets;
• labeling consistency with the reference product.

What is the Orange Book status of valganciclovir?

Valcyte is listed in the FDA Orange Book as a reference product for valganciclovir hydrochloride oral products. The major market opportunity is generic substitution rather than new chemical entity exclusivity.

The original Valcyte patent estate centered on valganciclovir, the L-valyl ester prodrug of ganciclovir. U.S. Patent No. 6,083,953, assigned to Syntex, covered the compound and was later associated with Roche’s Valcyte franchise. Public patent records identify a nominal term ending in 2017, subject to applicable patent-term adjustment, patent-term extension and pediatric exclusivity calculations.[2] The core compound protection is therefore expired, and generic products are commercially established.

Protection category	Commercial status
Valganciclovir active ingredient	Expired core protection
Valcyte tablet formulation	No practical current barrier to ordinary generic competition
Oral-solution formulation	Potential for formulation-specific claims, but conventional products remain exposed to competition
Method-of-use protection	Historical protection may have covered CMV treatment or prevention; current commercial impact is limited
Pediatric exclusivity	Historical, time-limited regulatory extension
Biosimilar protection	Not applicable because valganciclovir is a small molecule

The Orange Book should be reviewed for the current patent-listing snapshot before a launch or litigation decision. Patent listings can change through delisting, expiration or administrative updates.

When did valganciclovir lose exclusivity?

Valganciclovir lost meaningful market exclusivity after expiration of the principal compound patent and the end of associated regulatory exclusivities. Generic approvals followed, and the market now operates under ordinary abbreviated-application competition.

The relevant timing sequence is:

Event	Timing
Valcyte FDA approval	2001
Principal compound patent term	Public records indicate expiration in 2017, subject to term adjustments
Generic development and Paragraph IV activity	Began before or around the end of the principal patent term
Generic market entry	Established after reference-product exclusivity barriers ended
Current status	Mature generic market with formulation and supply-chain competition

There is no current biosimilar pathway issue. A biosimilar applicant would not be appropriate because valganciclovir is not a biologic under the Public Health Service Act.

Which companies are challenging or competing with Valcyte?

Competition has come from generic pharmaceutical manufacturers rather than biosimilar developers. U.S. generic competition has included companies such as Dr. Reddy’s Laboratories and other ANDA sponsors, although the active supplier set can change through discontinuations, shortages and product transfers.

The competitive landscape has three segments:

1. Standard 450 mg tablets.
2. Generic powder for oral solution.
3. Institutional and specialty-distribution suppliers serving transplant and infectious-disease centers.

The strongest commercial differentiation is likely to come from:

• reliable availability of the oral solution;
• smaller minimum order quantities;
• pediatric-friendly taste;
• robust reconstitution instructions;
• dual-source excipient procurement;
• lower tablet manufacturing cost;
• supply continuity during generic market exits.

What formulation patents could protect a new valganciclovir product?

A new formulation would need claims that distinguish it from routine excipient substitution. Potential claim areas include:

• taste-masked valganciclovir particles;
• controlled-release or delayed-release dosage forms;
• stabilized oral suspensions;
• low-moisture powder systems;
• specific preservative and pH combinations;
• improved redispersibility;
• unit-dose oral-solution sachets;
• drug-device combinations for accurate pediatric dosing;
• manufacturing processes that reduce degradation products.

A formulation patent is stronger when it links a defined composition to a measurable technical result, such as improved chemical stability, reduced bitterness, faster dissolution or a longer in-use period. Broad claims covering familiar excipients at ordinary concentrations face greater validity and obviousness risk.

Method-of-use claims may target pediatric CMV prevention, transplant protocols or renal-dose administration. Their practical value depends on prescribing behavior, label carve-outs and the ability to detect infringement. Method patents are less effective when the same product has broad approved uses and generic labels can omit protected indications.

How strong is the patent estate for oral valganciclovir?

The legacy estate is weak as a barrier to conventional generic entry because the core compound protection has expired and the product has been genericized. A newly developed excipient platform could create a moderate patent position if it provides measurable performance advantages and is commercially adopted.

Estate component	Relative strength
Core molecule	Low, expired
Conventional tablet excipients	Low
Standard film coating	Low
Pediatric taste masking	Moderate if technically specific
Oral-solution stability system	Moderate if supported by comparative data
Dosing device integration	Moderate, depending on claim scope
Manufacturing process	Variable; strongest where impurity reduction is demonstrated
Method of use	Limited by label strategy and enforcement practicality

Freedom-to-operate analysis should cover patents directed to taste masking, oral suspensions, coating technologies, pediatric dosing devices and excipient combinations, not only valganciclovir-specific patents.

What generic launch risks exist for valganciclovir?

The main risks are commercial and technical rather than basic patent risk.

Manufacturing and quality barriers

High drug loading increases sensitivity to blend uniformity, tablet weight and compression behavior. Moisture and temperature can accelerate degradation or alter powder handling. Oral-solution products add reconstitution, preservative and microbiological requirements.

Market-size risk

Valganciclovir is a specialty generic with demand linked to transplant activity, CMV incidence and hospital or specialty-pharmacy purchasing. A small number of suppliers can create price volatility, but low total volume may limit the return on a complex differentiated formulation.

Label and substitution risk

A tablet generic may not capture patients requiring oral solution. A pediatric formulation with better taste may command a premium only if prescribers, transplant centers and caregivers recognize the administration advantage.

Supply-chain risk

Specialty products can be vulnerable to a single-source active ingredient, limited contract manufacturing capacity or excipient shortages. Dual sourcing of critical excipients and validated alternate suppliers can create a commercial advantage.

What licensing deals affect valganciclovir?

The principal commercial history involves Roche’s Valcyte franchise and generic licensing or settlement arrangements associated with ANDA litigation. Publicly visible opportunities today are more likely to involve contract manufacturing, regional commercialization, oral-solution technology or pediatric drug-device systems than licensing the expired core molecule.

A licensing transaction would be most defensible where it transfers:

• a validated taste-masking platform;
• a stable powder-for-reconstitution process;
• a pediatric dosing device;
• regional registration rights;
• manufacturing capacity for a scarce oral-solution presentation.

A license focused only on the valganciclovir active ingredient would have limited strategic value because the core compound is off patent.

How does valganciclovir compare with competing CMV therapies?

Product or therapy	Route	Competitive relationship
Valganciclovir	Oral	Convenient outpatient prodrug of ganciclovir
Ganciclovir	Intravenous or other non-oral use	Used when oral therapy is unsuitable or absorption is a concern
Foscarnet	Intravenous	Alternative for resistant or refractory CMV; higher administration burden
Cidofovir	Intravenous	Alternative with substantial renal and administration limitations
Letermovir	Oral or intravenous	Mainly CMV prophylaxis in selected transplant populations; different indication and mechanism
Maribavir	Oral	Treatment of refractory or resistant CMV in defined transplant populations

Valganciclovir retains a commercial role where oral administration and established clinical use outweigh toxicity, monitoring and resistance concerns. Its main formulation opportunity is improving administration rather than changing the underlying antiviral mechanism.

What commercial opportunities exist in valganciclovir excipients?

The most credible opportunities are:

1. A pediatric oral solution with improved taste and dosing accuracy.
2. A lower-cost tablet process with stable dissolution across manufacturing sites.
3. A longer in-use stability profile after reconstitution.
4. A unit-dose oral-solution package for transplant centers.
5. A ready-to-use suspension that reduces pharmacy compounding steps.
6. A moisture-protective package using standard, widely available excipients.
7. A dual-source excipient system that reduces supply interruptions.
8. A formulation with lower sedimentation and better redispersibility.
9. A co-packaged oral syringe calibrated to the approved concentration.
10. A regional product tailored to markets where tablets dominate but pediatric liquid supply is limited.

The highest-value concept is likely a pediatric formulation that combines taste masking, accurate dosing and operational stability without creating a burdensome manufacturing process.

Key Takeaways

• Valganciclovir hydrochloride is a mature generic small-molecule market with no biosimilar pathway.
• The principal commercial products are 450 mg film-coated tablets and 50 mg/mL oral solution after reconstitution.
• Conventional tablet excipients offer limited patent differentiation.
• Taste masking, oral-solution stability, redispersibility and dosing-device integration offer the strongest formulation opportunities.
• The original compound patent estate is expired or commercially non-blocking; public records identify U.S. Patent No. 6,083,953 as a principal historical patent with a term ending in 2017, subject to applicable adjustments.
• Generic launch risk is driven mainly by manufacturing complexity, supply continuity, pediatric usability and market size.
• A new product should pursue composition claims tied to measurable technical performance rather than routine excipient substitution.

FAQs

Can valganciclovir hydrochloride be formulated as a ready-to-use liquid?

Yes. A ready-to-use suspension is technically possible, but it must address chemical stability, microbial control, sedimentation, redispersibility and in-use shelf life. The regulatory burden is higher than for a conventional powder-for-reconstitution product.

Which excipient is most important for valganciclovir taste masking?

No single excipient is sufficient. The strongest approach generally combines a sweetener, flavor system, pH adjustment and, where justified, a physical taste-masking technology such as coating or ion exchange.

Is a new valganciclovir formulation eligible for a new patent?

Potentially. Patentability is strongest when the formulation has a defined composition and demonstrated improvement in stability, palatability, dissolution, redispersibility or dosing performance. Routine substitution of common tablet excipients is less likely to produce strong protection.

Does valganciclovir require a Paragraph IV certification today?

A new ANDA applicant must assess the current Orange Book patent listings and certify against any listed patents. Because the principal historical compound protection has expired, the principal certification risk is generally lower than during the original generic-entry period, but current listings must control the filing strategy.

What is the most attractive commercial niche for valganciclovir?

A pediatric oral-solution product with superior taste, reliable reconstitution, accurate dosing and dependable supply is the clearest niche. It addresses a practical limitation that standard 450 mg tablets cannot solve.

References

1. U.S. Food and Drug Administration. (2024). Valcyte (valganciclovir hydrochloride) prescribing information.
2. U.S. Patent and Trademark Office. (2000). U.S. Patent No. 6,083,953: L-valyl ester of ganciclovir.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
5. National Library of Medicine. (2024). DailyMed: Valganciclovir hydrochloride drug labeling.